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NT-proBNP as a Mediator of the Racial Difference in Incident Atrial
Fibrillation and Heart Failure
Isaac R. Whitman, MD; Eric Vittinghoff, PhD; Christopher R. DeFilippi, MD John S. Gottdiener, MD; Alvaro Alonso, MD, PhD; Bruce M. Psaty,
MD, PhD; Susan R. Heckbert, MD, PhD; Ron C. Hoogeveen, PhD; Dan E. Arking, PhD; Elizabeth Selvin, PhD, MPH; Lin Y. Chen, MD, MS;
Thomas A. Dewland, MD; Gregory M. Marcus, MD, MAS
Background-—Blacks harbor more cardiovascular risk factors than whites, but experience less atrial fibrillation (AF). Conversely,
whites may have a lower risk of heart failure (CHF). N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are higher in
whites, predict incident AF, and have diuretic effects in the setting of increased ventricular diastolic pressures, potentially providing
a unifying explanation for these racial differences.
Methods and Results-—We used data from the CHS (Cardiovascular Health Study) to determine the degree to which baseline NT-
proBNP levels mediate the relationships between race and incident AF and CHF by comparing beta estimates between models with
and without NT-proBNP. The ARIC (Atherosclerosis Risk in Communities) study was used to assess reproducibility. Among 4731
CHS (770 black) and 12 418 ARIC (3091 black) participants, there were 1277 and 1253 incident AF events, respectively. Whites
had higher baseline NT-proBNP (CHS: 40% higher than blacks; 95% CI, 29–53; ARIC: 39% higher; 95% CI, 33–46) and had a greater
risk of incident AF compared with blacks (CHS: adjusted hazard ratio, 1.60; 95% CI, 1.31–1.93; ARIC: hazard ratio, 1.93; 95% CI,
1.57–2.27). NT-proBNP levels explained a significant proportion of the racial difference in AF risk (CHS: 36.2%; 95% CI, 23.2–
69.2%; ARIC: 24.6%; 95% CI, 14.8–39.6%). Contrary to our hypothesis, given an increased risk of CHF among whites in CHS
(adjusted hazard ratio, 1.20; 95% CI, 1.05–1.47) and the absence of a significant association between race and CHF in ARIC
(adjusted hazard ratio, 1.07; 95% CI, 0.94–1.23), CHF-related mediation analyses were not performed.
Conclusions-—A substantial portion of the relationship between race and AF was statistically explained by baseline NT-proBNP
levels. No consistent relationship between race and CHF was observed. ( J Am Heart Assoc. 2019;8:e010868. DOI: 10.1161/
JAHA.118.010868.)
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A trial fibrillation (AF) is the most common cardiacarrhythmia in the United States and the leading cause
of embolic stroke.1,2 Hypertension and congestive heart
failure (CHF) are 2 of the most important risk factors for
development of AF.3,4 However, despite the finding that these
and other AF risk factors are more common in blacks,5–11
whites have a greater risk for AF,12–15 as do American blacks
with greater European ancestry.16 The pathophysiology
underlying this paradox is unknown. Similarly, in some
populations, blacks also have a substantially higher risk for
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CHF than whites,6 but the mechanism underlying this
difference is not completely understood.
Of interest, AF is associated with higher ANP (atrial natriuretic
peptide) levels.17,18 Evidence that genetic aberrations in the ANP
gene are associated with AF19 raises the question as to whether
abnormalities in ANP expression may cause AF (rather than
reflect an atrial myopathy secondary to AF). Furthermore, serum
levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide)
have been closely correlated with ANP,17,20–22 have similarly
been shown to predict incident AF,17,23–25 and are known to have
diuretic effects that might relieve volume overload in the setting
of CHF.26–28 Recent evidence demonstrates that NT-proBNP
levels are lower in blacks.29 Therefore, it is plausible that NT-
proBNP levels might mediate the discordant race-AF and race-
CHF associations. Specifically, the higher baseline level of
natriuretic peptides in whites may have a direct atrial effect that
increases AF susceptibility.Wehypothesized that higher levels of
NT-proBNP at baseline in the absence of elevated filling
pressures, by the diuretic action of this protein, may also render
whites less prone to CHF.
Understanding these relationships might help to elucidate
the mechanisms underlying both of these important diseases
and may point to specific prediction strategies and novel
treatment approaches informed by racial background.
We sought to quantify the racial differences in incident AF
and CHF, and then determine the degree to which NT-proBNP
levels may mediate the racial differences between blacks and
whites in incident AF and CHF.
Methods
Using the CHS (Cardiovascular Health Study) and then subse-
quently the ARIC (Atherosclerosis Risk in Communities) Study
population as an independent replication cohort, we measured
the degree to which NT-proBNP level at baselinemay explain the
differential relationship between race and incident AF and CHF
in prospective, population-based cohort studies. The authorswill
make themethods (codes for the statistical analysis) available to
any researcher for purposes of reproducing the results. The data
belong to CHS and ARIC, and the authors therefore do not have
the authority to share the study data with investigators outside
the University of California, San Francisco (San Francisco, CA);
however, investigators can submit an application to obtain the
data directly from the CHS or the ARIC Study using their
established processes.
Recruitment, characterization, and outcome ascertainment
in the CHS and ARIC have been previously published.30,31 Each
cohort’s research protocol was approved by its respective
institutional review board, and all participants provided written
informedconsent. The specificmethodsof theCHSandARICare
summarized below. Criteria for baseline ascertainment of
hypertension, coronary heart disease, CHF, and diabetes
mellitus for each cohort are described in Table S1.
Cardiovascular Health Study
CHS is a prospective, community-based cohort study designed
to follow patients aged ≥65 years to assess cardiovascular risk
factors and outcomes, the methods for which have previously
been described.31 AF and CHF ascertainment was complete
through 2008, during which timemedical records were obtained
for all hospitalizations.31 Prevalent AF was identified from the
baseline ECG,32 and incident AF was identified from study visit
ECGs and hospital discharge diagnoses. Incident CHF was
identified through self-report, hospital diagnosis codes, and in-
and outpatient medical records adjudicated by the CHS Cardiac
Events Subcommittee.33
Levels of NT-proBNP were measured from blood samples
taken at study entry. Methods were the same for both the
main cohort (1989–1990) and in the additional cohort of
black participants (1992–1993). Serum was initially frozen
and stored at 70°C to 80°C until testing, which occurred
between 2007 and 2008. All testing was performed in a lab
certified by the Clinical Laboratory Improvement Amendments
and accredited by the College of American Pathologists. A US
Food and Drug Administration–approved immunoassay was
used for NT-proBNP measurement on an Elecsys 2010
instrument (Roche Diagnostics, Indianapolis, IN). The coeffi-
cient of variation for the NT-proBNP assay was 2% to 5%
during the testing period, and the analytical measurement
range for NT-proBNP was 5 to 35 000 pg/mL. The core
laboratory reported data to the central data repository and
was blinded to patient outcomes.23,34
ARIC Study
The ARIC Study is a prospective study of 15 792 primarily
white and black middle-aged participants recruited from 4
Clinical Perspective
What Is New?
• The paradoxical observation that whites exhibit a higher risk
of atrial fibrillation than blacks despite generally harboring
fewer conventional atrial fibrillation risk factors may be
partially explained by higher NT-proBNP (N-terminal pro-B-
type natriuretic peptide) levels in whites.
What Are the Clinical Implications?
• Better understanding the effects of NT-proBNP in the atria
may elucidate why higher NT-proBNP levels are associated
with atrial fibrillation and may provide a potential therapeu-
tic target for atrial fibrillation prevention.
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communities in the United States between 1987 and 1989, as
described previously.30 Prevalent AF was identified from the
intake ECG, and incident AF was identified from study visit
ECGs, hospital discharge diagnoses, and death certificates
through 2013.35 Prevalent CHF was ascertained through
medication review, self-report questionnaire, and physical
exam. Incident CHF was diagnosed through annual phone
interviews about interim hospitalizations, from hospital
discharge diagnosis codes, and death certificates, also
through 2013.36
Using serum samples from visit 2 (1990–1992) stored at
70°C in EDTA, NT-proBNP levels were measured in ARIC
using a sandwich immunoassay method (Roche Diagnostics)
on a Roche Elecsys 2010 Analyzer in 2012–2013. The
measuring range of the assay was 5 to 35 000 pg/mL, and
the reliability coefficient for blinded replicate measurements
was 0.99 (n=418 pairs).37
Statistical Analysis
We conducted 2 separate analyses with AF and CHF as
respective outcomes. After assessing baseline NT-proBNP
levels at study entry (CHS) and visit 2 (ARIC), and excluding
patients with prevalent AF or CHF, we determined the associ-
ation between white or black race and incident AF or CHF, in
respective analyses, and then the degree to which the differ-
ences were statistically explained by baseline NT-proBNP level.
To deal with the right skewness of NT-proBNP and the
nonlinearity of its association with cardiovascular events,
NT-proBNP values were log2-transformed for analysis. After
excluding patients with baseline AF or CHF, analyses in both
the CHS and ARIC were adjusted for the following covariates
ascertained during the baseline visit: age, sex, body mass
index, diabetes mellitus, hypertension, coronary artery
disease, left ventricular hypertrophy, chronic kidney disease
(in CHS), creatinine (in ARIC), smoking status, alcohol
consumption, level of education, and income.
Cox proportional hazards regressionmodels adjusted for the
above covariates were then used to estimate the race-AF and
race-CHF associations. Proportional hazard assumptions were
tested and confirmed using log-log survival plots, comparison of
Kaplan–Meier and predicted survival plots, and tests for the
correlation of scaled Schoenfeld residuals with time.
The degree to which baseline NT-proBNP may explain the
differential racial association with AF or CHF was calculated
as the percentage change in the point estimate for race after
addition of NT-proBNP to the multivariate Cox model for AF.38
CIs for the percentage change were obtained using bootstrap
resampling. Because there was no evidence that whites
exhibited a lower risk of CHF in CHS or ARIC after adjustment,
no mediation analysis for NT-proBNP was performed in either
cohort for the CHF analyses.
Results
CHS Participants and NT-proBNP by Race
Of the 5888 participants in CHS, 4731 were included in the
analyses after exclusions. Participant characteristics at base-
line are shown in Table 1. On average, blacks had lower income
and less education than whites. Blacks had more hypertension
and diabetes mellitus at baseline, were more likely to have
smoked, and consumed less alcohol at baseline. Whites
exhibited a higher baseline NT-proBNP than blacks (Table 1),
and after log transformation and multivariable adjustment,
whites had a 40%higher NT-proBNP than blacks (95%CI, 29–53;
P<0.001; unadjusted, 29%; 95% CI, 19–41; P<0.001; Figure 1).
ARIC Participants and NT-proBNP by Race
After exclusion, 12 418 ARIC participants were included in
these analyses. Their characteristics are shown in Table 1. In
ARIC, blacks were, on average, younger than whites, a greater
proportion were female, and blacks had less education and
lower annual income. Black participants had a higher bodymass
index, on average, and a higher prevalence of baseline
hypertension, diabetes mellitus, and left ventricular hypertro-
phy. Whites had more coronary artery disease at baseline and
were more likely to have ever smoked or consumed alcohol.
Whites had higher NT-proBNP at baseline than blacks (Table 1)
and, with log transformation and multivariable adjustment, 39%
higher baseline NT-proBNP than blacks, on average (95% CI,
33–46; P<0.001; unadjusted, 55% higher NT-proBNP than
blacks, on average; 95% CI, 54–56; P<0.001; Figure 1).
AF in the CHS
CHS participants were followed for a mean of 11.8 years in
the AF analysis, accumulating 1277 incident AF events.
Whites had a greater risk of incident AF both before (hazard
ratio [HR], 1.32; 95% CI, 1.12–1.58; P=0.001) and after
multivariable adjustment (HR, 1.60; 95% CI, 1.31–1.93;
P<0.001; Figure 2). Furthermore, each doubling of NT-proBNP
increased the risk of incident AF by 46% (95% CI, 40–52;
P<0.001) after adjusting for age, sex, body mass index,
hypertension, diabetes mellitus, coronary artery disease, left
ventricular hypertrophy, chronic kidney disease, ever smok-
ing, drinks per week, education, and income.
Mediation analysis demonstrated that the percent of racial
differences in AF risk statistically explained by NT-proBNP was
36% (Table 2).
AF in the ARIC
Follow-up for a mean of 18.2 years yielded 1253 incident AF
events. As in CHS, whites in ARIC had a greater risk of
DOI: 10.1161/JAHA.118.010868 Journal of the American Heart Association 3
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incident AF (unadjusted HR, 1.53; 95% CI, 1.32–1.77;
P<0.001; adjusted HR, 1.93; 95% CI, 1.57–2.27; P<0.001;
Figure 2). After adjustment, a doubling of baseline NT-proBNP
was associated with an increased risk of incident AF by over
50% (adjusted, 56%; 95% CI, 50–63%; P<0.001; unadjusted,
62%; 95% CI, 56–68; P<0.001).
Comparing models with and without NT-proBNP included,
differences in baseline NT-proBNP statistically explained
nearly 25% of the increase in incident AF among whites
(Table 2).
CHF in CHS
Participants were followed for a mean of 10.9 years, with
1354 incident CHF events. Before adjustment, white race
was associated with lower incidence of CHF (HR, 0.87;
95% CI, 0.75–1.01; P=0.07). After adjustment, contrary to
what had been hypothesized, there was an increased risk
of incident CHF with white race (HR, 1.20; 95% CI, 1.05–
1.47; P=0.01; Figure 2). Sequential addition of each
covariate into the unadjusted model was performed, and
the increased risk of CHF in whites after adjustment could
not be attributed to any single variable alone; however,
diabetes mellitus, hypertension, and income exhibited the
largest effects (Table S2). Furthermore, in the CHS cohort
as a whole, there was an increased risk of CHF with
doubling of baseline NT-proBNP (45% increased risk; 95%
CI, 41–52; P<0.001; adjusted, 34% increased risk; 95% CI,
29–40; P<0.001)—again, contrary to our hypothesis that
higher baseline NT-proBNP in the absence of clinical AF or
CHF would have a protective association with CHF.
Because there was no increased risk of incident CHF with
black race after adjustment, a mediation analysis was not
performed.
Table 1. Baseline Participant Characteristics by Race in CHS and ARIC*
CHS (n=4731) ARIC (n=12 418)
Black (n=770) White (n=3961) P Value Black (n=3091) White (n=9327) P Value
Age, mean (SD), y 72.6 (5.6) 72.4 (5.4) 0.37 53.4 (5.8) 54.2 (5.7) <0.001
Male, n (%) 281 (37) 1559 (39) 0.14 1055 (37) 4275 (46) <0.001
Annual income, n (%) <0.001 <0.001
<$12 000 365 (51) 781 (20) 1012 (37) 531 (6)
≥$12 000 357 (49) 2926 (80) 1745 (63) 8406 (94)
Education, n (%) <0.001 <0.001
≤ High school† 531 (70) 2511 (64) 1988 (67) 5681 (62)
≥ Some college 228 (30) 1438 (36) 965 (33) 3555 (38)
NT-proBNP level, median (Q1, Q3), pg/mL 88.0 (43.2, 183.3) 113.6 (60.0, 215.0) <0.001 44.2 (23.0, 87.2) 56.7 (31.3, 99.1) <0.001
Body mass index, mean (SD), kg/m2 28.5 (5.5) 26.2 (4.4) <0.001 29.4 (6.0) 26.8 (4.7) <0.001
Hypertension, n (%) 564 (73) 2167 (55) <0.001 1331 (43) 1784 (19) <0.001
Diabetes mellitus, n (%) 176 (23) 531 (13) <0.001 483 (17) 736 (8) <0.001
Coronary artery disease, n (%) 126 (16) 605 (15) 0.44 88 (3) 418 (5) 0.001
Left ventricular hypertrophy, n (%)‡ 226 (29) 622 (16) <0.001 158 (6) 79 (1) <0.001
Chronic kidney disease, n (%) 113 (15) 540 (14) 0.44   
Creatinine, mean (SD), mg/dL    1.13 (0.5) 1.08 (0.2) <0.001
Ever smoker, n (%) 122 (16) 439 (11) <0.001 1518 (51) 5403 (59) <0.001
Alcoholic drinks/week, median (Q1, Q3) 0 (0, 0.25) 0.02 (0, 1.27) 0.0001   
Ever drinker, n (%)    1625 (55) 7568 (82) <0.001
Incident atrial fibrillation, n (%) 146 (19) 1131 (29) <0.001 212 (7) 1041 (11) <0.001
Incident heart failure, n (%) 215 (28) 1139 (29) 0.64 550 (19) 1195 (13) <0.001
NT-proBNP indicates N-terminal pro-B-type natriuretic peptide; Q1, Q3, first and third quartiles; CHS, Cardiovascular Health Study; ARIC, Atherosclerosis Risk in Communities Study.
*Years of enrollment and ascertainment of baseline characteristics for the Cardiovascular Health Study (whites: 1989–1990; blacks: 1992–1993) and Atherosclerosis Risk in Communities
study (1987–1989).
†Includes some or graduation from vocational school.
‡By electrocardiographic criteria.
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CHF in ARIC
Study participants were followed for a mean of 18.8 years,
accumulating 1783 incident CHF diagnoses. In an unadjusted
Cox proportional hazard model, white race was associated
with a lower incidence of CHF (HR, 0.66; 95% CI, 0.59–0.73;
P<0.001; Figure 2). This association disappeared with adjust-
ment, resulting in no association between race and incident
CHF (HR, 1.07; 95% CI, 0.94–1.23; P=0.32). Covariates were
individually added to the unadjusted model, and the addition
of income alone eliminated the statistical racial difference in
incident CHF (Table S3). No other single variable alone
eliminated statistical significance in the model. Similar to the
finding in CHS, there was in increased risk of CHF with
doubling of baseline NT-proBNP (unadjusted increased risk,
62%; 95% CI, 56–68; P<0.001; adjusted, 58%; 95% CI, 51–64;
P<0.001). Because there was no association of race with
incident CHF in ARIC, a mediation analysis for NT-proBNP was
not performed.
Discussion
Utilizing baseline NT-proBNP levels before the diagnoses of AF
or CHF, we found that higher NT-proBNP statistically
explained a significant proportion of the racial difference
noted in incident AF in 2 large, community-based studies.
However, contrary to our hypothesis, higher baseline NT-
proBNP levels in the absence of clinical AF or CHF were not
protective against incident CHF in either CHS or ARIC after
taking potential confounders into account, and there was no
disparate racial association with incident CHF.
NT-proBNP and AF
The paradoxical racial association with AF in various popula-
tions has been a point of interest in the literature.12,39–42 The
cardiac risk factors for AF have been well defined in multiple
population studies and have similarly been shown to be more
common in blacks than whites.5–9 Despite this, whites
experience a greater risk of AF,12 as do blacks with a greater
proportion of European ancestry.16
A potential explanation for this paradox—that, despite
fewer independent risk factors for AF, whites have a higher
risk for AF than blacks—may be mechanistically related to
natriuretic peptides, higher levels of which have been
associated with incident AF17,18,23,43 and circulating levels
of which are higher in whites than blacks.29,44 Presence of AF
has been associated with higher natriuretic peptides both
acutely and chronically,45–48 and natriuretic peptide levels
have been shown to decrease after cardioversion of AF,
illustrating that AF itself may increase natriuretic peptide
levels.49,50 However, because higher levels of baseline
natriuretic peptide predict incident AF, the relationship likely
goes “both ways.”23 More-elevated levels of natriuretic
peptide have been associated with atrial dysfunction,51 atrial
fibrosis,52 and a shorter atrial effective refractory period,53 all
characteristics known to enhance the probability of AF and
even mechanistically serve as a cause.54–56 In fact, in a case
of familial AF, a mutation in the gene expressing ANP was
mechanistically linked to the AF phenotype.19 In the current
study, despite substantial differences in absolute baseline NT-
proBNP levels between the CHS and ARIC (likely related to the
differences in age between the cohorts), the relationships
between every doubling of NT-proBNP levels and increased
risk of AF were remarkably similar.
Consistent with our current findings, whites have previ-
ously been shown to exhibit higher levels of natriuretic
peptide levels than blacks, and the difference does not
Figure 1. (A) Baseline NT-proBNP levels and (B) adjusted relative
relationship between NT-proBNP level in whites versus blacks, on
average, in the Cardiovascular Health Study and Atherosclerosis
Risk in Communities study. (A) p<0.001 blacks vs. whites in both
cohorts. (B) p<0.001 percent difference in baseline NT-proBNP in
both cohorts. *Adjustment in the model was made for age, gender,
body mass index, hypertension, diabetes, coronary artery disease,
left ventricular hypertrophy, chronic kidney disease, ever smoker,
drinks per week, education, and income. †Adjustment in the model
wasmade for age, gender, bodymass index, hypertension, diabetes,
coronary artery disease, left ventricular hypertrophy, creatinine,
ever smoker, ever drinker, education, and income.
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appear to be related to more heart failure or volume
overload.29 Therefore, there is presumably some genetic
predisposition to releasing more NT-proBNP independent of
myocardial stretch or left ventricular end-diastolic pressure.
Similarly, whites have a higher risk of AF compared with
blacks unrelated to more-established cardiovascular risk
factors,12–14 and blacks with more European ancestry
(determined by genotyping) have a higher risk of AF,16
suggesting that the race-AF relationship is likely genetically
mediated. Our current mediation analysis is consistent with
the notion that propensity to have a higher NT-proBNP level
at baseline may explain some of the differential risk of AF by
race. This itself, in turn, raises the question as to whether
natriuretic peptides may have a direct causal relationship
with AF.
NT-proBNP and CHF
In designing the present study, we had hypothesized that
higher levels of baseline NT-proBNP, while potentially
imposing increased risk of AF for whites, may also
mediate the differential racial association with CHF
observed in some populations.6 The general theory is that
a higher NT-proBNP level, on average, would help maintain
diuresis and therefore help to mitigate volume overload. In
fact, we observed no increased risk of CHF in blacks
versus whites after adjustment in either CHS or ARIC, and
so the extent to which baseline NT-proBNP may mediate
the differential association was rendered moot in statistical
analyses. Indeed, although whites had greater risk for CHF
in CHS, there was no such association with CHF in ARIC.
Figure 2. Cumulative incidence of (A) atrial fibrillation and (B) heart failure in the Cardiovascular Health Study and Atherosclerosis Risk in
Communities Study, by race. *Adjustment in the model was made for age, sex, body mass index, hypertension, diabetes mellitus, coronary
artery disease, left ventricular hypertrophy, chronic kidney disease, ever smoker, drinks per week, education, and income. †Adjustment in the
model was made for age, sex, body mass index, hypertension, diabetes mellitus, coronary artery disease, left ventricular hypertrophy, creatinine,
ever smoker, ever drinker, education, and income.
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These observations themselves demonstrate that the
apparent racial propensity to differential NT-proBNP levels
does not translate into consistent differences in CHF
incidence. It is possible that the higher prevalence of CHF
risk factors among blacks is counterbalanced by a
protective effect of NT-proBNP, resulting in a net equiv-
alence of incident CHF.
Our findings regarding race and CHF are also consistent with
previous literature. In the MESA (Multiethnic Study of
Atherosclerosis), Bahrami et al concluded that blacks have
more incident CHF than whites; however, after adjustment for
hypertension and/or diabetes mellitus, that difference was
attenuated.6 Interestingly, data from the CARDIA (Coronary
Artery Risk Development in Young Adults) study clearly showed
that young blacks were at a substantially higher risk thanwhites
for CHF,57 more consistent with our findings in ARIC (a younger
population than that of CHS), where, after adjustment, risk for
CHF in whites and blacks was statistically equivalent. This may
suggest that there is an important interaction between age and
race that is relevant to CHF pathophysiology.
This study had several limitations. CHS and ARIC rely on
intake questionnaires for prevalence of diseases at baseline,
although review of medical records and surveys of treating
physicians were performed at baseline to identify prevalent
cardiovascular disease in CHS. The current study lacked
echocardiography data or other direct measurements of filling
pressures to determine potential underlying mechanistic
relationships to baseline NT-proBNP levels. Self-report of
baseline comorbidities may limit the sensitivity and specificity
of disease prevalence at baseline, particularly with AF, which
cannot necessarily be refuted by ECG. The effects of the bias
this creates cannot be determined, but nonetheless the
sensitivity and specificity of the presence of diagnoses at
baseline is likely similar between the predictor groups in this
study and therefore may not affect comparative results.
Although NT-proBNP was measured in blood samples at study
entry, and those with prevalent AF or CHF were excluded from
the study, theremay have been occult AF or presence of certain
comorbidities at baseline, such as undetected hypertension,
that may have increased baseline NT-proBNP measurements
and similarly increased the risk of AF and CHF in those patients.
However, although this may have biased the analysis toward an
increased risk of AF and/or CHF in patients with higher NT-
proBNP, it would not appear to affect or explain the results of
the mediation analysis. Follow-up in both CHS and ARIC
included multiple visits, review of intervening medical records,
and serial ECGs; however, it remains possible that some AF
remained undetected. Nonetheless, more-sensitive monitoring
should generally affect the incidence of AF similarly in both
whites and blacks, but again should not affect the mediation
analysis. Whereas the statistical model of the study is meant to
address the possible role NT-proBNP may play in mediation of
the differential relationship between race and AF, the statistical
model is merely suggestive and not definitive of mediation or a
causal relationship. Also, there may be unmeasured con-
founders not captured by data available in CHS and ARIC,
although both of these cohorts include robust lifestyle and
demographic information, and all relevant covariates were
included in multivariable models. Finally, because this is an
observational study, the relationships described should be
interpreted as associations, and no conclusions regarding
causality can be made.
Table 2. Mediation Analysis Results for the Percent Effect Explained by NT-proBNP of the Racial Difference Between Blacks and
Whites in Incident AF
Predictor Outcome Measure Estimate
Cardiovascular Health Study*
Atherosclerosis Risk in
Communities†
Effect (95% CI) P Value Effect (95% CI) P Value
White race (vs black race) Baseline NT-proBNP Relative difference (% greater) 40.1 (28.6–52.5) <0.001 39.4 (32.7–46.4) <0.001
NT-proBNP‡ Incident AF Hazard ratio 1.39 (1.33–1.45) <0.001 1.56 (1.50–1.63) <0.001
White race (vs black race) Incident AF Hazard ratio, excluding
NT-proBNP from adjustment
1.60 (1.31–1.93) <0.001 1.93 (1.57–2.27) <0.001
White race (vs black race) Incident AF Hazard ratio, including
NT-proBNP in adjustment
1.34 (1.11–1.63) 0.002 1.64 (1.35–2.00) <0.001
White race (vs black race) Incident AF Percent effect explained
by NT-proBNP
36.2 (23.2–69.2) <0.001 24.6 (14.8–39.6) <0.001
AF indicates atrial fibrillation; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Adjustment in the model was made for age, sex, body mass index, hypertension, diabetes mellitus, coronary artery disease, left ventricular hypertrophy, chronic kidney disease, ever
smoker, drinks per week, education, and income.
†Adjustment in the model was made for age, sex, body mass index, hypertension, diabetes mellitus, coronary artery disease, left ventricular hypertrophy, creatinine, ever smoker, ever
drinker, education, and income.
‡The model of NT-proBNP as a predictor reflects the effect of a doubling of NT-proBNP.
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Conclusion
A substantial portion of the strong and paradoxical relationship
between white race and AF was explained by higher baseline
NT-proBNP levels in both a middle-aged and older adult
population. Conversely, despite the higher NT-proBNP levels
in whites, no consistent relationship between race and CHFwas
observed between the 2 cohorts. Given previous literature
demonstrating an atrial remodeling effect of natriuretic pep-
tides, these data draw attention to whether natriuretic peptides
may have a direct casual effect on AF, suggesting that targeting
such pathways to prevent or treat AF may prove fruitful.
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